350672-14-9

Basic information

• Product Name: 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE
• Synonyms: 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE
• CAS NO: 350672-14-9
• Molecular Formula: C₉H₆ClFN₂O
• Molecular Weight: 212.61
• Mol File: 350672-14-9.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE(350672-14-9)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE(350672-14-9)

Safety Data

• Hazardous Substances Data: 350672-14-9(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole is a chemical compound with the molecular formula C9H6ClFN2O. It is a member of the oxadiazole family and contains a chloromethyl group, a 4-fluorophenyl group and a 1,3,4-oxadiazole ring. 2-(CHLOROMETHYL)-5-(4-FLUOROPHENYL)-1,3,4-OXADIAZOLE has potential applications in the field of medicinal chemistry and drug development due to its interesting biological properties. It is also used as a building block in organic synthesis for the construction of more complex molecules. Further research and studies may reveal additional uses and properties of 2-(chloromethyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole.

Upstream product

• 403-33-8 methyl 4-flurobenzoate 
• 456-06-4 4-fluorobenzoyl hydrazide 
• 79-11-8 chloroacetic acid 
• 456-22-4 4-Fluorobenzoic acid 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 499129-05-4 N’-(chloroacetyl)-4-fluorobenzohydrazide 

Downstream Products

• 1622982-21-1 C₁₅H₉FN₄OS 
• 1202941-86-3 (6S)-6-{[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methoxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant articles and documents

Oxazole ring-containing honokiol thioether derivative and preparation method and application thereof

The invention discloses an oxazole ring-containing honokiol thioether derivative, a preparation method thereof and application of the oxazole ring-containing honokiol thioether derivative as an alpha-glucosidase inhibitor, the chemical structure of the oxazole ring-containing honokiol thioether derivative is shown as a general formula (I), and R is selected from non-substituted or substituted phenyl. Compared with the prior art, the invention provides the novel honokiol thioether derivative containing the oxazole ring, and the honokiol thioether derivative containing the oxazole ring has good inhibitory activity on alpha-glucosidase, provides more possibilities for treating diabetes, and is expected to be used for preparing novel candidate drug molecules for treating diabetes. In addition, the preparation process is simple, the cost is low, and the yield is high.

Synthesis and biological evaluation of honokiol derivatives bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3h)-ones as potential viral entry inhibitors against sars-cov-2

The 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 virus infection has posed a serious danger to global health and the economy. However, SARS-CoV-2 medications that are specific and effective are still being developed. Honokiol is a bioactive component from Magnoliae officinalis Cortex with damp-drying effect. To develop new potent antiviral molecules, a series of novel honokiol analogues were synthesized by introducing various 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones to its molecule. In a SARS-CoV-2 pseudovirus model, all honokiol derivatives were examined for their antiviral entry activities. As a result, 6a and 6p demonstrated antiviral entry effect with IC50 values of 29.23 and 9.82 μM, respectively. However, the parental honokiol had a very weak antiviral activity with an IC50 value more than 50 μM. A biolayer interfero-metry (BLI) binding assay and molecular docking study revealed that 6p binds to human ACE2 protein with higher binding affinity and lower binding energy than the parental honokiol. A competitive ELISA assay confirmed the inhibitory effect of 6p on SARS-CoV-2 spike RBD’s binding with ACE2. Importantly, 6a and 6p (TC50 > 100 μM) also had higher biological safety for host cells than honokiol (TC50 of 48.23 μM). This research may contribute to the discovery of potential viral entrance inhibitors for the SARS-CoV-2 virus, although 6p’s antiviral efficacy needs to be validated on SARS-CoV-2 viral strains in a biosafety level 3 facility.

Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential anti-oxidant and anti-inflammatory agents

Twenty benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety were synthesized and evaluated for their anti-oxidant and anti-inflammatory activities. Among these compounds, 8h and 8l were appeared to have high radical scavenging efficacies as 0.05 ± 0.02 and 0.07 ± 0.03 mmol/L of IC50 values in ABTS+[rad] bioassay, respectively. In anti-inflammatory tests, compound 8h displayed good activity with 57.35% inhibition after intraperitoneal administration, which was more potent than the reference drug (indomethacin). Molecular modeling studies were performed to investigate the binding mode of the representative compound 8h into COX-2 enzyme. In vitro enzyme study implied that compound 8h exerted its anti-inflammatory activity through COX-2 inhibition.